DOCSLIB.ORG

Summit on the Future Treatments in Migraine and Cluster Headaches Findings from the AMCP Market Insights Program

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Summit on the Future Treatments in Migraine and Cluster Headaches Findings from the AMCP Market Insights Program MARKET INSIGHTS Summit on the Future Treatments in Migraine and Cluster Headaches Findings from the AMCP Market Insights Program by attacks of throbbing, often unilateral pain that are Meeting Objective exacerbated by physical activity and associated with photophobia, phonophobia, nausea, vomiting, and, in • Understand how AMCP members identify and many patients, cutaneous allodynia.1 Severe headache manage members with migraine and cluster and migraine are common in the U.S., with 20% of women headaches and approximately 10% of men aged ≥ 18 years reporting • Identify how payers establish coverage criteria for they had at least one in the past 3 months.2 The burden of new migraine therapies illness is often substantial, attacks can significantly impair • Define key information required for payers to aid functional ability at work, school, home, and in social product differentiation, treatment protocols, and situations.3,4 utilization review to ensure optimal outcomes for Migraines are often described as recurrent throbbing members or pulsating, moderate to severe, and often unilateral pain • Define the role of non-pharmaceutical treatment that lasts 4-72 hours with complete freedom between options in patient management the attacks (episodic). The headache is associated with nausea, vomiting and/or sensitivity to light, sound or smell. Cluster headache affects only 0.1% of the population; but patients suffer severe unilateral pain mainly in the first Introduction division of the trigeminal nerve, with associated prominent Headache is one of the most common symptoms in the unilateral cranial autonomic symptoms and a sense of general population, but despite its high prevalence and agitation and restlessness during the attacks. impairment, migraine is of ten not recognized or effectively Cluster headache is less common, but the most treated. Researchers have been working for decades to prevalent in the category of headache disorder termed develop a “targeted” therapies specifically for headaches. trigeminal autonomic cephalalgia. Cluster headaches Fortunately, with aid from advanced technology and are characterized by the short duration, they are strictly clinical innovations, there are new treatment options unilateral and have accompanying autonomic features of available for patients - including CGRP inhibitors and to lacrimation, rhinorrhea, conjunctival injection and ptosis.6 other therapies headed for Food and Drug Administration The changing seasons are the most common trigger for (FDA) approval, and a growing class of non-pharmaceutical cluster headaches, which often occur in the spring or devices that work via nerve stimulation. As new classes of drugs and non-drug treatments come to market health care providers and payers will need up-to-date Figure 1. Market Insights Forum Participant Mix evidence and guidance for the use and coverage of novel treatments. To understand the appropriate and cost effective use of novel treatments, AMCP convened an expert 15% forum of stakeholders. Forum participants included representatives from regional and national health 31% plans, integrated delivery networks, 340b entities and pharmacy benefit managers. (Figure 1). Participants discussed the differentiation of migraine and cluster headaches, treatment and prevention therapies, pipeline 39% 15% pharmaceuticals and devices, and the impact of new treatments on formulary management and the delivery of care. Differentiation of Headaches Pharmacy Benefit Manager The most common primary headache disorders are IDN/health system or 340B hospital entity Regional payer tension-type headache, migraine, and cluster headache. Nationa health plan Migraine is a chronic neurologic disease characterized April 2020 Market Insights 1 MARKET INSIGHTS Summit on the Future Treatments in Migraine and Cluster Headaches Table 1. ICHD-3 Criteria for Episodic and Chronic Migraine5 Episodic migraine Chronic migraine A. At least 5 attacks fulfilling criteria B–D A. Migraine-like or tension-type-like headache on ≥ 15 days/ B. Headache attacks lasting 4-72 hours (when untreated or month for > 3 months that fulfill criteria B and C unsuccessfully treated) B. Occurring in a patient who has had at least 5 attacks fulfilling C. Headache has at least 2 of the following 4 characteristics: criteria B-D for migraine without aura and/or criteria B and C for migraine with aura 1. Unilateral location C. On ≥ 8 days/month for > 3 months, fulfilling any of the 2. Pulsating quality following: 3.Moderate or severe pain intensity 1. Criteria C and D migraine without aura 4.Aggravation by or causing avoidance of routine physical 2. Criteria B and C for migraine with aura activity (e.g., walking or climbing stairs) 3. Believed by the patient to be migraine at onset and relieved D. During headache at least 1 of the following: by a triptan or ergot derivative 1. Nausea and/or vomiting D. Not better accounted for by another diagnosis 2. Photophobia and phonophobia E. Not better accounted for by another diagnosis ICHD = International Classification of Headache Disorders. While cluster headaches and migraines are clinically “I don’t think the plan makes a good differentiated some managed care organizations are job of differentiating migraines challenged to separate out the headache diagnosis in their pharmacy claims data. Participants noted that the from cluster headaches. I think they specific type of headache may not always be able to be [cluster headaches and migraine] just determined with claims data, and raised the possible limitation of using claims data as there is thought to be get lumped in the same category. I general unawareness of the different diagnostic codes for would have no way, if I asked my data various types of headaches within pharmacy. Diagnostic delays can limit the ability to administer analyst to pull that out…” appropriate acute and preventative treatments. An analysis from the American Migraine Prevalence and Prevention autumn. Due to their seasonal nature, cluster headaches (AMPP) Study showed that the majority of individuals with are often mistakenly associated with allergies or sinusitis. migraine had not received a correct diagnosis (79.8%) nor Early acute treatment for both types of headaches specific acute (68.4%) or preventive (60.0%) medications.7 is important, and for patients not responding to over- However, patients consulting a specialist were nearly 1.5 the-counter nonspecific pain medications, the use of times more likely to receive a chronic migraine diagnosis specific migraine medications is recommended. The most than those consulting other HCPs. commonly used migraine specific medication class for acute treatment are “triptans” (5-hydroxytryptamine [5- “I think this access [to the HT] 1b/1d receptor agonists). Recent developments and the emergence of novel medications, device technologies, appropriate provider] is probably the and biologics have advanced treatment options for single biggest issue that we’re facing patients with migraine and cluster headaches. Diagnoses of migraine can be classified based on the in looking in some of these therapies frequency of monthly migraine days (MMDs) and monthly and some of these disease states.” headache days (MHDs); patients with fewer than 15 MMDs or MHDs have episodic migraine, and those with at The ability to access qualified physician specialists was least 15 MHDs, of which at least 8 are MMDs, have chronic discussed as a challenge due to the limited number of migraine (Table 1).2 About 2 to 3 percent of patients available headache specialists (approximately 500 UCNS with episodic migraine will transform to having chronic certified headache medicine specialists in the U.S.),8 migraine in a given year. neurologists, and geographical locations, e.g. rural vs. 2 Market Insights April 2020 MARKET INSIGHTS Summit on the Future Treatments in Migraine and Cluster Headaches Table 2. Pharmacotherapy with Evidence of Efficacy in Migraine Treatment8 Level A Level B Triptans Anti-emetics: DHE Nasal Spray IV Metoclopramide & Prochlorperazine NSAIDs: Anti-dopamine: Diclofenac, aspirin, naproxen, ibuprofen IV Chlorpromazine & Droperidol IV Acetaminophen Ergots: Acetaminophen/aspirin/caffeine 500/500/130 mg IM/IV DHE Acetaminophen 1000 mg (for non-incapacitating attacks) NSAIDS: Butorphanol nasal spray Ketorolac Opioids: Codeine/acetaminophen, Tramadol/acetaminophen Level A = Established as effective for the given condition in the specified population. (Level A rating requires at least two consistent Class I studies.)* Level B = Probably effective for the given condition in the specified population. (Level B rating requires at least one Class I study or at least two consistent Class II studies.) urban settings. As a result, patients often seek migraine care from their primary care physician (PCP). While initial Emerging Agents evaluation of headache care is appropriate by a non- Emerging agents with novel mechanisms of action that specialist clinician (e.g. PCP), several payers preferred have demonstrated efficacy for the acute treatment patients with severe headaches or those resistant to of migraine include the small molecule calcitonin gene-related peptide (CGRP) receptor antagonists, treatment see a specialist who could appropriately ubrogepant and rimegepant, and lasmiditan a evaluate the headache disorder and select subsequent selective serotonin (5 -HT1F) receptor agonist (Table 3). treatments. Unlike triptans and ergotamine derivatives, these To ensure optimal outcomes for their members, payers novel
Load more

Recommended publications
  • Cluster Headache: a Review MARILYN J
    • Cluster headache: A review MARILYN J. CONNORS, DO ID Cluster headache is a debilitat­ consists of episodes of excruciating facial pain that ing neuronal headache with secondary vas­ is generally unilateraP and often accompanied by cular changes and is often accompanied by ipsilateral parasympathetic phenomena including other characteristic signs and symptoms, such nasal congestion, rhinorrhea, conjunctival injec­ as unilateral rhinorrhea, lacrimation, and con­ tion, and lacrimation. Patients may also experi­ junctival injection. It primarily affects men, ence complete or partial Horner's syndrome (that and in many cases, patients have distinguishing is, unilateral miosis with normal direct light response facial, body, and psychologic features. Sever­ and mild ipsilateral ptosis, facial flushing, and al factors may precipitate cluster headaches, hyperhidrosis).4-6 These autonomic disturbances including histamine, nitroglycerin, alcohol, sometimes precede or occur early in the headache, transition from rapid eye movement (REM) adding credence to the theory that this constella­ to non-REM sleep, circadian periodicity, envi­ tion of symptoms is an integral part of an attack and ronmental alterations, and change in the level not a secondary consequence. Some investigators of physical, emotional, or mental activity. The consider cluster headache to exemplify a tempo­ pathophysiologic features have not been com­ rary and local imbalance between sympathetic and pletely elucidated, but the realms of neuro­ parasympathetic systems via the central nervous biology, intracranial hemodynamics, endocrinol­ system (CNS).! ogy, and immunology are included. Therapy The nomenclature of this form of headache in is prophylactic or abortive (or both). Treat­ the literature is extensive and descriptive, includ­ ment, possibly with combination regimens, ing such terminology as histamine cephalgia, ery­ should be tailored to the needs of the indi­ thromelalgia of the head, red migraine, atypical vidual patient.
    [Show full text]
  • Stand up to Chronic Migraine with Botox®
    #1 PRESCRIBED BRANDED TREATMENT FOR CHRONIC MIGRAINE* Chronic Migraine DON’T LIE DOWN BOTOX ® STAND UP TO Prevention CHRONIC MIGRAINE® WITH BOTOX Treatment Experience Treatment *Truven Health MarketScan Data, October 2010-April 2017. Prevent Headaches and Migraines Before They Even Start BOTOX ® BOTOX® prevents on average 8 to 9 headache days and migraine/probable migraine days a month (vs 6 to 7 for placebo) Savings Program For adults with Chronic Migraine, 15 or more headache days a month, each lasting 4 hours or more. BOTOX® is not approved for adults with migraine who have 14 or fewer headache days a month. Indication • Spread of toxin effects. The effect of botulinum toxin may affect areas BOTOX® is a prescription medicine that is injected to prevent headaches in adults away from the injection site and cause serious symptoms including: loss of with chronic migraine who have 15 or more days each month with headache strength and all-over muscle weakness, double vision, blurred vision and lasting 4 or more hours each day in people 18 years or older. drooping eyelids, hoarseness or change or loss of voice, trouble saying words It is not known whether BOTOX® is safe or effective to prevent headaches clearly, loss of bladder control, trouble breathing, trouble swallowing. in patients with migraine who have 14 or fewer headache days each month There has not been a confirmed serious case of spread of toxin effect away from (episodic migraine). the injection site when BOTOX® has been used at the recommended dose to IMPORTANT SAFETY INFORMATION treat chronic migraine. Resources BOTOX® may cause serious side effects that can be life threatening.
    [Show full text]
  • What Are the Acute Treatments for Migraine and How Are They Used?
    2. Acute Treatment CQ II-2-1 What are the acute treatments for migraine and how are they used? Recommendation The mainstay of acute treatment for migraine is pharmacotherapy. The drugs used include (1) acetaminophen, (2) non-steroidal anti-inflammatory drugs (NSAIDs), (3) ergotamines, (4) triptans and (5) antiemetics. Stratified treatment according to the severity of migraine is recommended: use NSAIDs such as aspirin and naproxen for mild to moderate headache, and use triptans for moderate to severe headache, or even mild to moderate headache when NSAIDs were ineffective in the past. It is necessary to give guidance and cautions to patients having acute attacks, and explain the methods of using medications (timing, dose, frequency of use) and medication use during pregnancy and breast-feeding. Grade A Background and Objective The objective of acute treatment is to resolve the migraine attack completely and rapidly and restore the patient’s normal functions. An ideal treatment should have the following characteristics: (1) resolves pain and associated symptoms rapidly; (2) is consistently effective; (3) no recurrence; (4) no need for additional use of medication; (5) no adverse effects; (6) can be administered by the patients themselves; and (7) low cost. Literature was searched to identify acute treatments that satisfy the above conditions. Comments and Evidence The acute treatment drugs for migraine generally include (1) acetaminophens, (2) non-steroidal anti-inflammatory drugs (NSAIDs), (3) ergotamines, (4) triptans, and (5) antiemetics. For severe migraines including status migrainosus and migraine attacks refractory to treatment, (6) anesthetics, and (7) corticosteroids (dexamethasone) are used (Tables 1 and 2).1)-9) There are two approaches to the selection and sequencing of these medications: “step care” and “stratified care”.
    [Show full text]
  • Migraine; Cluster Headache; Tension Headache Order Set Requirements: Allergies Risk Assessment / Scoring Tools / Screening: See Clinical Decision Support Section
    Provincial Clinical Knowledge Topic Primary Headaches, Adult – Emergency V 1.0 © 2017, Alberta Health Services. This work is licensed under the Creative Commons Attribution-Non-Commercial-No Derivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. Disclaimer: This material is intended for use by clinicians only and is provided on an "as is", "where is" basis. Although reasonable efforts were made to confirm the accuracy of the information, Alberta Health Services does not make any representation or warranty, express, implied or statutory, as to the accuracy, reliability, completeness, applicability or fitness for a particular purpose of such information. This material is not a substitute for the advice of a qualified health professional. Alberta Health Services expressly disclaims all liability for the use of these materials, and for any claims, actions, demands or suits arising from such use. Revision History Version Date of Revision Description of Revision Revised By 1.0 March 2017 Topic completed and disseminated See Acknowledgements Primary Headaches, Adult – Emergency V 1.0 Page 1 of 16 Important Information Before You Begin The recommendations contained in this knowledge topic have been provincially adjudicated and are based on best practice and available evidence. Clinicians applying these recommendations should, in consultation with the patient, use independent medical judgment in the context of individual clinical circumstances to direct care. This knowledge topic will be reviewed periodically and updated as best practice evidence and practice change. The information in this topic strives to adhere to Institute for Safe Medication Practices (ISMP) safety standards and align with Quality and Safety initiatives and accreditation requirements such as the Required Organizational Practices.
    [Show full text]
  • Pharmacokinetics, Pharmacodynamics and Drug
    pharmaceutics Review Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies Danuta Szkutnik-Fiedler Department of Clinical Pharmacy and Biopharmacy, Pozna´nUniversity of Medical Sciences, Sw.´ Marii Magdaleny 14 St., 61-861 Pozna´n,Poland; [email protected] Received: 28 October 2020; Accepted: 30 November 2020; Published: 3 December 2020 Abstract: In the last few years, there have been significant advances in migraine management and prevention. Lasmiditan, ubrogepant, rimegepant and monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) are new drugs that were launched on the US pharmaceutical market; some of them also in Europe. This publication reviews the available worldwide references on the safety of these anti-migraine drugs with a focus on the possible drug–drug (DDI) or drug–food interactions. As is known, bioavailability of a drug and, hence, its pharmacological efficacy depend on its pharmacokinetics and pharmacodynamics, which may be altered by drug interactions. This paper discusses the interactions of gepants and lasmiditan with, i.a., serotonergic drugs, CYP3A4 inhibitors, and inducers or breast cancer resistant protein (BCRP) and P-glycoprotein (P-gp) inhibitors. In the case of monoclonal antibodies, the issue of pharmacodynamic interactions related to the modulation of the immune system functions was addressed. It also focuses on the effect of monoclonal antibodies on expression of class Fc gamma receptors (FcγR). Keywords: migraine; lasmiditan; gepants; monoclonal antibodies; drug–drug interactions 1. Introduction Migraine is a chronic neurological disorder characterized by a repetitive, usually unilateral, pulsating headache with attacks typically lasting from 4 to 72 h.
    [Show full text]
  • Autonomic Headache with Autonomic Seizures: a Case Report
    J Headache Pain (2006) 7:347–350 DOI 10.1007/s10194-006-0326-y BRIEF REPORT Aynur Özge Autonomic headache with autonomic seizures: Hakan Kaleagasi Fazilet Yalçin Tasmertek a case report Received: 3 April 2006 Abstract The aim of the report is the criteria for the diagnosis of Accepted in revised form: 18 July 2006 to present a case of an autonomic trigeminal autonomic cephalalgias, Published online: 25 October 2006 headache associated with autonom- and was different from epileptic ic seizures. A 19-year-old male headache, which was defined as a who had had complex partial pressing type pain felt over the seizures for 15 years was admitted forehead for several minutes to a with autonomic complaints and left few hours. Although epileptic hemicranial headache, independent headache responds to anti-epilep- from seizures, that he had had for tics and the complaints of the pre- 2 years and were provoked by sent case decreased with anti- watching television. Brain magnet- epileptics, it has been suggested ౧ A. Özge ( ) • H. Kaleagasi ic resonance imaging showed right that the headache could be a non- F. Yalçin Tasmertek hippocampal sclerosis and elec- trigeminal autonomic headache Department of Neurology, troencephalography revealed instead of an epileptic headache. Mersin University Faculty of Medicine, Mersin 33079, Turkey epileptic activity in right hemi- e-mail: [email protected] spheric areas. Treatment with val- Keywords Headache • Non-trigemi- Tel.: +90-324-3374300 (1149) proic acid decreased the com- nal autonomic cephalalgias • Fax: +90-324-3374305 plaints. The headache did not fulfil Autonomic seizure • Valproic acid lateral autonomic phenomena and/or restlessness or agita- Introduction tion [3].
    [Show full text]
  • Current and Prospective Pharmacological Targets in Relation to Antimigraine Action
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Erasmus University Digital Repository Naunyn-Schmiedeberg’s Arch Pharmacol (2008) 378:371–394 DOI 10.1007/s00210-008-0322-7 REVIEW Current and prospective pharmacological targets in relation to antimigraine action Suneet Mehrotra & Saurabh Gupta & Kayi Y. Chan & Carlos M. Villalón & David Centurión & Pramod R. Saxena & Antoinette MaassenVanDenBrink Received: 8 January 2008 /Accepted: 6 June 2008 /Published online: 15 July 2008 # The Author(s) 2008 Abstract Migraine is a recurrent incapacitating neuro- (CGRP1 and CGRP2), adenosine (A1,A2,andA3), glutamate vascular disorder characterized by unilateral and throbbing (NMDA, AMPA, kainate, and metabotropic), dopamine, headaches associated with photophobia, phonophobia, endothelin, and female hormone (estrogen and progesterone) nausea, and vomiting. Current specific drugs used in the receptors. In addition, we have considered some other acute treatment of migraine interact with vascular receptors, targets, including gamma-aminobutyric acid, angiotensin, a fact that has raised concerns about their cardiovascular bradykinin, histamine, and ionotropic receptors, in relation to safety. In the past, α-adrenoceptor agonists (ergotamine, antimigraine therapy. Finally, the cardiovascular safety of dihydroergotamine, isometheptene) were used. The last two current and prospective antimigraine therapies is touched decades have witnessed the advent of 5-HT1B/1D receptor upon. agonists (sumatriptan and second-generation triptans), which have a well-established efficacy in the acute Keywords 5-HT. Antimigraine drugs . CGRP. treatment of migraine. Moreover, current prophylactic Noradrenaline . Migraine . Receptors treatments of migraine include 5-HT2 receptor antagonists, Ca2+ channel blockers, and β-adrenoceptor antagonists. Despite the progress in migraine research and in view of its Introduction complex etiology, this disease still remains underdiagnosed, and available therapies are underused.
    [Show full text]
  • Headache: a Patient's Guide (Pdf)
    Headache A Patient’s Guide Kathleen Digre, MD • Susan Baggaley, APRN • K.C. Brennan, MD • Seniha Ozudogru, MD 729 Arapeen Drive Salt Lake City, Utah 84108 801.585.7575 headache.uofuhealth.org Headache: A Patient’s Guide eadache is an extremely common problem. It is estimated that 10-20% of all people have migraine. Headache is one of the most common reasons H people visit the doctor’s office. Headache can be the symptom of a serious problem, or it can be recurrent, annoying and disabling, without any underlying structural cause. WHAT CAUSES HEAD PAIN? Pain in the head is carried by certain nerves that supply the head and neck. The trigeminal system impacts the face as well as the cervical (neck) 1 and 2 nerves in the back of the head. Although pain can indicate that something is pushing on the brain or nerves, most of the time nothing is pushing on anything. We think that in migraine there may be a generator of headache in the brain which can be triggered by many things. Some people’s generators are more sensitive to stimuli such as light, noise, odor, and stress than others, causing a person to have more frequent headaches. THERE ARE MANY TYPES OF HEADACHES! Most people have more than one type of headache. The most common type of headache seen in a doctor's office is migraine (the most common type of headache in the general population is tension headache). Some people do not believe that migraine and tension headaches are different headaches, but rather two ends of a headache continuum.
    [Show full text]
  • The Migraine-Epilepsy Syndrome
    medigraphic Artemisaen línea Arch Neurocien (Mex) Vol 11, No. 4: 282-287, 2006 The Migraine- Epilepsy Syndrome Arch Neurocien (Mex) Vol. 11, No. 4: 282-287, 2006 Artículo de revisión ©INNN, 2006 de caso The migraine-epilepsy syndrome Enrique Otero Siliceo†, Fernando Zermeño EL SINDROME MIGRAÑA-EPILEPSIA represent a neural exitation. Since that the glutamate has in important rol in both patologys depending of the part of the brain more affected the symptoms might RESUMEN vary from visual to abdominal phemomena. La migraña y la epilepsia tienen varios puntos en común Key words: migraine epilepsy, EEG abnormalities, sintomática clínica y genéticamente lo que ha sido glutamate, diagnosis. postulado por más de cien años. El fenómeno referido como migraña-epilepsia sugiere que exista una he first steps of a practical, approach by patofisiología común. El síndrome de migraña o physicians in recognizing and treating neuro- epilepsia tiene fenómenos comunes de dolor adominal T logic diseases are to recognithat there are jaqueca anormalidades del EE y respuesta a droga various overlaps between migraine and epilepsy. antiepilépticas. En ocasiones el paciente puede tener Epileptic seizures and classic migraine episodes may un ataque migrañoso o una convulsión o en otras occur in the same patient. Migraine and epilepsy share ambas. La comorbilidad puede explicarse por estados several genetic, clinical, evolutive and neurophysio- de hiperrexcitabilidad neural. Alteraciones electroen- logic features. A relationship between epilepsy and cefalográficas son comunes en estos estados. En migraine has been postulated for over a hundred years apariencia el glutamato tiene un papel importante tanto and the syndrome of Migraine-Epilepsy illustrates this en la migraña como en la epilepsia.
    [Show full text]
  • Journal of Neurological Disorders DOI: 10.4172/2329-6895.1000275 ISSN: 2329-6895
    olog eur ica N l D f i o s l o a r n d r e u r s o J Derakhshan, J Neurol Disord 2016, 4:4 Journal of Neurological Disorders DOI: 10.4172/2329-6895.1000275 ISSN: 2329-6895 Research Article Open Access Successful Opioid Monotherapy in Migralepsy: A Case Series Iraj Derakhshan* Department of Neurology, Case Western Reserve and Cincinnati Universities, Ohio, USA *Corresponding author: Iraj Derakhshan, Associate Professor, Department of Neurology, Case Western Reserve and Cincinnati Universities, Ohio, 205 Cyrus Drive, Charleston West Virginia, 25314, USA, Tel: 304 345 5174; E-mail: [email protected] Rec date: June 10, 2016; Acc date: July 06, 2016; Pub date: July 10, 2016 Copyright: © 2016 Derakhshan I. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Background: There is a consensus that migraine and epilepsy are comorbid conditions. The novel concept explored and developed in this case series is that of the primacy of headaches in generating seizures in those patients suffering from migraine-triggered epilepsy (i.e., migralepsy). As demonstrated in the five cases descried here, much like the effect of ketogenic-diet on migraine-triggered epilepsy, once the migraine headaches were completely suppressed after adopting daily scheduled opioid therapy the seizures stopped from occurring, but they returned with the recurrence of the migraines once the patients had stopped their daily opiate regimen for any reason. Clinical implications: The above pharmacological scenario is reminiscent of a similar but naturalistic course of events as described in reports concerning the salutary effects of ketogenic diet, or restoration of sleep, in cases of migraine-triggered epilepsy.
    [Show full text]
  • Migraine Mimics
    ISSN 0017-8748 Headache doi: 10.1111/head.12518 © 2015 American Headache Society Published by Wiley Periodicals, Inc. Expert Opinion Migraine Mimics Randolph W. Evans, MD The symptoms of migraine are non-specific and can be present in many other primary and secondary headache disorders, which are reviewed. Even experienced headache specialists may be challenged at times when diagnosing what appears to be first or worst, new type, migraine status, and chronic migraine. Key words: migraine, migraine mimic, symptomatic migraine, hemicrania continua (Headache 2015;55:313-322) The symptoms of migraine are non-specific and She had seen 2 headache specialists previously. can be present in many other primary and secondary She had been tried on sumatriptan p.o. and subcuta- headache disorders.1,2 Even experienced headache neously, diclofenac powder, ketorolac oral and intra- specialists may be challenged at times when diagnos- muscular, dihydroergotamine nasal spray, and had an ing what appears to be first or worst, new type, occipital nerve block without benefit. Gabapentin migraine status, and chronic migraine. Another diag- and pregabalin did not help. She was placed on indo- nosis may be responsible when physicians use the term methacin 75 mg sustained release once a day for 8 “atypical migraine.” days without benefit. Prednisone 60 mg daily for 10 days did not help.An intravenous dihydroergotamine CASE HISTORIES regimen for 5 days did not help. Case 1.—This 48-year-old woman was seen for a A magnetic resonance imaging (MRI) and mag- third opinion with a 20-year history of only menstrual netic resonance angiogram (MRA) of the brain and headaches always preceded by a visual aura followed cervical spine and magnetic resonance venogram by a generalized throbbing with an intensity of 5–6/10 (MRV) of the brain were negative.
    [Show full text]
  • Primary Headaches and Their Relationship with Sleep Cefaleias Primárias E Sua Relação Com O Sono
    Yagihara F, Lucchesi LM‚ Smith AKA, Speciali JG 28 REVIEW ARTICLE Primary headaches and their relationship with sleep Cefaleias primárias e sua relação com o sono Fabiana Yagihara1, Ligia Mendonça Lucchesi1, Anna Karla Alves Smith1, José Geraldo Speciali2 ABSTRACT pain control systems. In general, pain affects sleep and vice There is a clear association between primary headaches and sleep versa(1,2). We found that primary headaches with no clear disorders, especially when these headaches occur at night or upon etiology by clinical and laboratory tests can be triggered by waking. The primary headaches most commonly related to sleep either short or long periods of sleep, or by interrupted or are: migraine, cluster headache, tension type, hypnic headache and (3) chronic paroxysmal hemicrania. The objective of this review was to non-restorative sleep . Sleep is also effective in relieving describe the relationship between these types of headaches and sle- symptoms: 85% of individuals with migraine report that ep and to address sleep apnea headaches. There are various types of they choose to sleep or rest because of a headache, and demonstrated associations between sleep and headache disorders, many are forced to do it(4). Therefore, headaches and sleep and the mechanisms underlying these associations are complex, multi-factorial and poorly understood. Moreover, all sleep disorders disturbances are common and often coexist in the same may be related to headaches to some degree; therefore, the evalua- individual(3,5), and this association is especially observed tion of patients with headaches should include a brief investigation when these headaches occur at night or upon waking(6,7).
    [Show full text]